Results 41 to 50 of about 39,159 (175)

Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance [PDF]

, 2022
In this pilot clinical trial, we evaluated rates of residual replication in persons without lamivudine resistance-associated mutations in proviral DNA population sequencing who switched to dolutegravir plus lamivudine.
Pinto, Adriana, Jimenez-Gonzalez, María, Lagarde, Maria, Bisbal, Otilia, Rubio, Rafael, Montejano, Rocío, Hernando, Asunción, Delgado, Rafael, Arribas, José Ramón, Santacreu-Guerrero, Mireia, Bermejo-Plaza, Laura, Pulido, Federico, Antiretroviral Treatment Guided by Proviral Genotype (ART-PRO) Study Group, Rial-Crestelo, David, Martín-Carbonero, Luz, Castro, Juan Miguel, Moreno, Victoria, Esteban-Cantos, Andrés, Cadiñanos, Julen, Aranguren-Rivas, Paula, De Miguel Buckley, Rosa   +20 more
core   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Susceptibility of Primary HTLV-1 Isolates from Patients with HTLV-1-Associated Myelopathy to Reverse Transcriptase Inhibitors

Viruses, 2011
Since human T-lymphotropic virus type 1 (HTLV-1)-associated diseases are associated with a high HTLV-1 load, reducing this load may treat or prevent disease.
Antonio Mastino, Graham P Taylor, Beatrice Macchi, Emanuela Balestrieri, Arianna Ascolani, Silva Hilburn, Fabiola Martin   +6 more
doaj   +1 more source

Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection [PDF]

, 2003
Liver-related mortality is an increasing problem in human immunodeficiency virus (HIV)/hepatitis B virus (HBV)-coinfected patients receiving highly active antiretroviral therapy (HAART).
Gilson, RJ, Maini, MK, Bertoletti, A, Lascar, RM, Lopes, AR   +4 more
core  

The Emerging Role of China in the Innovation, Individualization, and Translation of Antiviral Therapeutics for Chronic Hepatitis B

Portal Hypertension &Cirrhosis, EarlyView.
This perspective outlines China's contributions toward functional‐cure‐oriented antiviral therapies for chronic hepatitis B, summarizing key clinical data on bepirovirsen and domestic drug pipelines with balanced coverage of both promising and disappointing trial results.
Dandan Weng, Zhujun Cao, Qing Xie
wiley   +1 more source

Clinical characteristics of 89 HIV-positive patients coinfected with lamivudine-resistant or lamivudine-susceptible hepatitis B virus

, 2016
Clinical characteristics of 89 HIV-positive patients coinfected with lamivudine-resistant or lamivudine-susceptible hepatitis B ...
Sui-Yuan Chang (39460), Hsin-Yun Sun (61134), Kuan-Yeh Lee (523493), Yi-Ching Su (734372), Shan-Chwen Chang (91714), Wang-Huei Sheng (103262), Wen-Chun Liu (61140), Yu-Shan Huang (847180), Chien-Ching Hung (61132), Yu-Chung Chuang (236282)   +9 more
core   +1 more source

Clinical trial of lamivudine in children with chronic hepatitis B. [PDF]

, 2002
BACKGROUND: Lamivudine therapy is effective for chronic hepatitis B infection in adults. We evaluated the efficacy and tolerability of lamivudine as a treatment for chronic infection with hepatitis B virus (HBV) in children.
Schwarz, KB, Jonas, M.M., Kelley, Deirdre A, Bell, M Steve, Greensmith, M.J., Bell, MS, Schwarz, K.B., Kelly, Deirdre, Schwarz, Kathleen B, Aerias, JA, International Pediatric Lamivudine Investigator Group., Gardener, SD, Greensmith, MJ, Bell, M.S., Mierski, J, Sokal, E.M., Badia, Isabel B, Greensmith, Martin J, Little, N.R., Little, Nancy R, Little, NR, Jonas, MM, Jonas, Maureen M, Mizerski, Jacek, Gardner, Stephen D, Sokal, EM, Badia, IB, Areias, Jorge A, Badia, I.B., Sokal, Etienne, Gardner, S.D., Areias, J.A., Mizerski, J.   +32 more
core   +1 more source

Development and Characterization of Printlets of Lamivudine for Pediatric Patients Using Selective Laser Sintering

Pharmaceuticals
Background: Lamivudine is widely used alone or in combination with other anti-HIV drugs in the infant to adolescent age groups of pediatric populations. Compounding of medications is frequently used for pediatric patients.
Canberk Kayalar, Swaroop Jalandar Pansare, Gereziher Sibhat, Mathew Kuttolamadom, Ziyaur Rahman, Mansoor A. Khan   +5 more
doaj   +1 more source

Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta

Alimentary Pharmacology &Therapeutics, EarlyView.
In patients with chronic hepatitis Delta, the LGP2 Q425R variant (rs2074158 CC/CT genotypes), associated with an enhanced interferon response in vitro, becomes progressively less frequent as liver disease advances from no cirrhosis to cirrhosis, and to cirrhosis with progressive increase of portal hypertension evaluated by thrombocytopenia.
Sara Cmet, Elisabetta Degasperi, Annarosa Cussigh, Elisabetta Fontanini, Maria Paola Anolli, Floriana Facchetti, Riccardo Perbellini, Dana Sambarino, Sara Colonia Uceda Renteria, Annapaola Callegaro, Davide Bitetto, Elisa Fumolo, Ezio Fornasiere, Elena Garlatti Costa, Edmondo Falleti, Pietro Lampertico, Pierluigi Toniutto   +16 more
wiley   +1 more source

On‐Treatment Reassessment of Type IV Collagen 7S and M2BPGi‐Qt Improves Long‐Term Hepatocellular Carcinoma Risk Stratification in Chronic Hepatitis B

Hepatology Research, EarlyView.
One‐year reassessment of type IV collagen 7S, supported by quantitative M2BPGi‐Qt assessment, helped refine long‐term hepatocellular carcinoma risk stratification in patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy. On‐treatment 4COL7S emerged as a novel marker of residual fibrosis‐related HCC risk.
Kazumi Yamasaki, Hideko Kozuru, Tomoko Sato, Tomoyuki Suehiro, Yasuhide Motoyoshi, Yuki Kugiyama, Akira Saeki, Shinya Nagaoka, Atsumasa Komori, Hiroshi Yatsuhashi   +9 more
wiley   +1 more source